Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 454-459

  Ikeguchi, Masahide ^a   Ueda, Tsuyoshi ^a   Fukuda, Kenji ^a   Yamaguchi, Ken ichi ^a   Tsujitani, Shun ichi ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal squamous cell carcinoma; Immunohistochemistry; Murine double minute (MDM2) protein; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PROGNOSIS; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036793833     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00006     Document Type: Article

References (39)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
3. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A 1990;87:9958-61.
4. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-50.
5. Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-9.
6. Huang Y, Meltzer SJ, Yin J, et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
7. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
8. Cahilly-Snyder L, Yang-Feng T, Francke U, et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987;13:235-44.
9. Geyer RK, Yu ZK, Maki CG. The MDM2 ring-finger domain is required to promote p53 nuclear export. Natur Cell Biol 2000;2:569-73.
10. Xiao Z-X, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-8.
11. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
12. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-34.
13. Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
14. Landers JE, Haines DS, Straus JF, et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-50.
15. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-78.
16. Würl P, Meye A, Berger D, et al. Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma. Langenbecks Arch Surg 1998;383:99-103.
17. Endo K, Ueda T, Ohta T, et al. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000;20:209-15.
18. Haitel A, Wiener HG, Baethge U, et al. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6:1840-4.
19. Suzuki A, Toi M, Yamamoto Y, et al. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998;89:221-7.
20. Naunheim KS, Petruska PJ, Roy TS, et al. Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 1992;103:887-95.
21. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992;127:1446-50.
22. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 1997;80:1011-20.
23. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-9.
24. Mukaida H, Hirai T, Yamashita Y, et al. Clinical evaluation of adjuvant chemotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer. Jpn J Thorac Cardiovasc Surg 1998;46:11-7.
25. Sobin LH, Wittekind CH. UICC TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss, 1997.
26. Sarbia M, Porschen R, Borchard F, et al. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
27. Ikeguchi M, Oka S, Gomyou Y, et al. Combined analysis of p53 and retinoblastoma protein expression in esophageal cancer. Ann Thorac Surg 2000;70:913-7.
28. Coupland SE, Anastassiou G, Stang A, et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 2000;191:120-6.
29. Siewert JR, Roder JD. Lymphadenectomy in esophageal cancer surgery. Dis Esoph 1992;2:91-7.
30. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991;48:411-20.
31. Fahn H-J, Wang L-S, Huang B-S, et al. Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus. Ann Thorac Surg 1994;57:677-81.
32. Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997;226:162-8.
33. Ikeguchi M, Oka S, Gomyo Y, et al. Clinical significance of retinoblastoma protein (pRB) expression in esophageal squamous cell carcinoma. J Surg Oncol 2000;73:104-8.
34. Martin K, Trouche D, Hagemeier C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995;375:691-4.
35. Morgan RJ, Newcomb PV, Hardwick RH, et al. Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma. Eur J Surg Oncol 1999;25:364-7.
36. Minsky BD. The adjuvant treatment of esophageal cancer. Semin Radiat Oncol 1994;4:165-9.
37. Lehnert T. Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg 1999;86:727-39.
38. Meng RD, Shin H, Prabhu NS, et al. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 1998;4:251-9.
39. Tortora G, Caputo R, Damiano V, et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000;88:804-9.